SCHEMBL7990401

SCHEMBL7990401

CCN(CC)C(=O)/C=C(\C)c1cc(OCC(=O)O)cc(OCc2ccccc2F)c1

nearest known ligand 0.73

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 18/20 0.73
LTB4R2 Q9NPC1 18/20 0.73
MAOB P27338 1/20 0.46
RARA P10276 1/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
GCK P35557 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7990403 1.00 LTB4R (0.73) LTB4RLTB4R2MAOBRARARARB
SCHEMBL7990405 1.00 LTB4R (0.73) LTB4RLTB4R2MAOBRARARARB
SCHEMBL7994001 0.89 LTB4R (0.72) LTB4RLTB4R2
SCHEMBL7994009 0.89 LTB4R (0.72) LTB4RLTB4R2
SCHEMBL7994006 0.89 LTB4R (0.72) LTB4RLTB4R2
SCHEMBL7988629 0.88 LTB4R (0.73) LTB4RLTB4R2MAOB
SCHEMBL7988639 0.88 LTB4R (0.73) LTB4RLTB4R2MAOB
SCHEMBL7988633 0.88 LTB4R (0.73) LTB4RLTB4R2MAOB
SCHEMBL7989763 0.86 LTB4R (0.71) LTB4RLTB4R2MAOB
SCHEMBL7990289 0.86 LTB4R (0.71) LTB4RLTB4R2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6207686-B1 FOR THERAPY OF HYPERTENSION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-27 US claimed
EP-0636133-A1 SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-02-01 EP claimed
WO-1993021186-A1 SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-10-28 WO claimed
EP-0341557-A1 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid derivatives and their preparation FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-11-15 EP claimed
US-4468515-A CEPRALOSPORINS, MICROBIOCIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-08-28 US claimed
US-4381299-A 7-Amino-thiadiazole oxyimino derivatives of cephem and cepham compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-04-26 US claimed
US-4332798-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-06-01 US claimed
US-6291530-B1 Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity NOVARTIS AG (CH) 2001-09-18 US disclosed
EP-0942903-A1 ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY Novartis AG (CH) 1999-09-22 EP disclosed
WO-1998013347-A1 ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY NOVARTIS AG (CH) 1998-04-02 WO disclosed
US-5608056-A Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-03-04 US disclosed
EP-0747381-A1 CARBAPENEM DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-12-11 EP disclosed
EP-0636133-A1 SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-02-01 EP disclosed
US-4468515-A CEPRALOSPORINS, MICROBIOCIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-08-28 US disclosed
US-4425340-A ANTIBIOTICS, BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-01-10 US disclosed
US-4390534-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-06-28 US disclosed
US-4381299-A 7-Amino-thiadiazole oxyimino derivatives of cephem and cepham compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-04-26 US disclosed
EP-0064582-A1 Starting compounds for preparing cephem compounds and processes for their preparation FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-11-17 EP disclosed
US-4332798-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-06-01 US disclosed
US-4331665-A ANTIBIOTICS, BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-05-25 US disclosed